Related Experiment Video
Updated: Sep 10, 2025
Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
Published on: June 7, 2012
Recurrent Ischemic Stroke and Vaginal Estradiol in Women With Prior Ischemic Stroke: A Nationwide Nested Case-Control
Kimia Ghias Haddadan1,2, Camilla Eckert-Lind1,2, Amani Meaidi3
1Department of Cardiology (K.G.H., C.E.-L., N.D.J., M.C.H.L., K.G.S., G.G., T.B.-S., D.M.), Copenhagen University Hospital-Herlev and Gentofte, Denmark.
Background:
Systemic estrogen replacement therapy is contraindicated in women with a history of ischemic stroke due to the risk of stroke recurrence. There are currently no published data available describing the association between vaginal estrogen use and recurrent ischemic stroke in women with a history of ischemic stroke. This study aimed to examine the association between vaginal estradiol tablet use and the rate of recurrent ischemic stroke in women with a history of ischemic stroke.
Methods:
Using nationwide registers, we conducted a nationwide nested case-control study including all women aged ≥45 years who developed a first ischemic stroke between January 1, 2008, and December 31, 2017, with no history of vaginal estrogen use before stroke diagnosis. Using incidence density sampling, we matched cases with recurrent ischemic stroke 1:1 to controls based on birth year. The index date was defined as the date of recurrent ischemic stroke diagnosis. Exposure to vaginal estradiol tablets was assessed using prescription data and categorized as current use (0-3 months before index), recent use (3-24 months before index), and past use (>24 months before index).
Results:
From a cohort of 56 642 women with a first-time stroke, we identified 3353 recurrent cases, which were matched by birth year with 3353 controls. The median age was 75 (SD, 12) years. When adjusted for comorbidity, medications, income, and education, exposure to vaginal estradiol tablets was not associated with an increased rate of recurrent ischemic stroke (current use: adjusted hazard ratio, 0.79 [95% CI, 0.52-1.20]; P=0.27; recent use: adjusted hazard ratio, 1.09 [95% CI, 0.73-1.63]; P=0.67; and past use: adjusted hazard ratio, 1.48 [95% CI, 0.95-2.30]; P=0.08).
Conclusions:
In this nested case-control study, use of vaginal estradiol tablets was not associated with an increased rate of recurrent ischemic stroke in women with a history of ischemic stroke. Based on our findings, vaginal estradiol tablets are not likely to increase the risk of recurrent ischemic stroke in women with prior stroke.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
02:58Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles
Published on: December 22, 2023
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis I: Introduction
01:27Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
01:27Pulmonary Embolism III: Nursing Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...